Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

Similar articles for PubMed (Select 22114098)

1.

Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?

Keefe RS, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M, Stewart M.

Schizophr Bull. 2013 Mar;39(2):417-35. doi: 10.1093/schbul/sbr153. Epub 2011 Nov 22. Review.

2.

The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR.

Am J Psychiatry. 2008 Feb;165(2):203-13. doi: 10.1176/appi.ajp.2007.07010042. Epub 2008 Jan 2.

PMID:
18172019
3.

The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?

Buchanan RW, Keefe RS, Umbricht D, Green MF, Laughren T, Marder SR.

Schizophr Bull. 2011 Nov;37(6):1209-17. doi: 10.1093/schbul/sbq038. Epub 2010 Apr 21.

4.

Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.

Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP.

J Clin Psychiatry. 2009 Jan;70(1):104-12. Epub 2008 Nov 18. Review.

PMID:
19026265
5.

[Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].

Bralet MC, Navarre M, Eskenazi AM, Lucas-Ross M, Falissard B.

Encephale. 2008 Dec;34(6):557-62. doi: 10.1016/j.encep.2007.12.005. Epub 2008 Jul 9. French.

PMID:
19081451
6.

The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.

Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Mintz J, Seidman LJ, Stover E, Marder SR.

Am J Psychiatry. 2008 Feb;165(2):214-20. doi: 10.1176/appi.ajp.2007.07010043. Epub 2008 Jan 2.

PMID:
18172018
7.

Cognitive functioning in first-episode schizophrenia: MATRICS Consensus Cognitive Battery (MCCB) Profile of Impairment.

McCleery A, Ventura J, Kern RS, Subotnik KL, Gretchen-Doorly D, Green MF, Hellemann GS, Nuechterlein KH.

Schizophr Res. 2014 Aug;157(1-3):33-9. doi: 10.1016/j.schres.2014.04.039. Epub 2014 Jun 2.

PMID:
24888526
8.
9.

A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia.

Pietrzak RH, Olver J, Norman T, Piskulic D, Maruff P, Snyder PJ.

J Clin Exp Neuropsychol. 2009 Oct;31(7):848-59. doi: 10.1080/13803390802592458. Epub 2009 Jan 14.

PMID:
19142774
10.

Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.

Keefe RS, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A.

Schizophr Res. 2011 Feb;125(2-3):161-8. doi: 10.1016/j.schres.2010.09.015. Epub 2010 Dec 31.

PMID:
21075600
11.

[MATRICS consensus cognitive battery--standard for the assessment of cognitive functions in clinical trials in schizophrenia].

Jedrasik-Styła M, Ciołkiewicz A, Denisiuk M, Linke M, Parnowska D, Gruszka A, Jarema M, Wichniak A.

Psychiatr Pol. 2012 Mar-Apr;46(2):261-71. Polish.

PMID:
23214396
12.

The MATRICS consensus cognitive battery (MCCB): co-norming and standardization in Spain.

Rodriguez-Jimenez R, Bagney A, Garcia-Navarro C, Aparicio AI, Lopez-Anton R, Moreno-Ortega M, Jimenez-Arriero MA, Santos JL, Lobo A, Kern RS, Green MF, Nuechterlein KH, Palomo T.

Schizophr Res. 2012 Feb;134(2-3):279-84. doi: 10.1016/j.schres.2011.11.026. Epub 2011 Dec 20.

PMID:
22192501
13.

Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?

Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, Woerner MG, Schooler NR, Kane JM, Robinson DG.

Arch Gen Psychiatry. 2007 Oct;64(10):1115-22.

PMID:
17909123
14.

Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial.

Chung YC, Lee CR, Park TW, Yang KH, Kim KW.

World J Biol Psychiatry. 2009;10(2):156-62.

PMID:
19514097
15.

A comparative study of the MATRICS and IntegNeuro cognitive assessment batteries.

Silverstein SM, Jaeger J, Donovan-Lepore AM, Wilkniss SM, Savitz A, Malinovsky I, Hawthorne D, Raines S, Carson S, Marcello S, Zukin SR, Furlong S, Dent G.

J Clin Exp Neuropsychol. 2010 Nov;32(9):937-52. doi: 10.1080/13803391003596496. Epub 2010 May 7. Erratum in: J Clin Exp Neuropsychol. 2010 Dec;32(10):1149.

PMID:
20455131
16.

The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.

Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L.

Schizophr Res. 2004 Jun 1;68(2-3):283-97.

PMID:
15099610
17.

Ginseng for cognition.

Geng J, Dong J, Ni H, Lee MS, Wu T, Jiang K, Wang G, Zhou AL, Malouf R.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD007769. doi: 10.1002/14651858.CD007769.pub2. Review.

PMID:
21154383
18.

Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy.

Ferreri F, Agbokou C, Gauthier S.

J Psychiatry Neurosci. 2006 Nov;31(6):369-76. Review.

19.

Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment.

Fioravanti M, Flicker L.

Cochrane Database Syst Rev. 2001;(4):CD003159. Review.

PMID:
11687175
20.

Assessing cognitive function in clinical trials of schizophrenia.

Barnett JH, Robbins TW, Leeson VC, Sahakian BJ, Joyce EM, Blackwell AD.

Neurosci Biobehav Rev. 2010 Jul;34(8):1161-77. doi: 10.1016/j.neubiorev.2010.01.012. Epub 2010 Jan 25.

PMID:
20105440
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk